In March 2014 the UK Early Access to Medicines Scheme (EAMS) was launched, and within two weeks an Adaptive Licencing pilot scheme (AL) was also launched by the European Medicines Agency (EMA). These two programs present new opportunities to enable drugs earlier access to market, giving patients with rare diseases quicker access to potentially life saving drugs.
We asked similar questions on these topics to notable figures within the industry and collated their views into the ebooks below, sharing their opinion on whether EAMS and AL are positive moves and what the UK can do to further orphan drugs access to market.
- Geoffrey Guy, Founder and Chairman of GW Pharmaceuticals
- Martin Andrews, Senior Vice President of Rare Diseases GSK
- Robert Meadowcroft, Chief Executive of the Muscular Dystrophy Campaign
- Mark Corbett, Senior Vice President at Clinigen Global Access Programs
Download their reports by clicking on the links above.
- Whether or not EAMS and AL are a positive step forward
- Top 5 recommendations for moving forward
- How the UK currently rates in comparison with other global access programs
Interested in their views why not join us for the Fast Tracking Orphan Drugs Briefing on 10th July to hear them speak on this very topic. All four senior industry experts will be sharing their opinion on these schemes and how can they shape the industry moving forward. Click here to book your place – its not too late!